Emmaus Life SciencesEMMA PS Ratio is 0.05 as of Jun. 28, 2026, which is 98% below its 10-year median of 2.31. The stock has 6 warning signs investors should review. Among 936 Biotechnology companies, Emmaus Life Sciences ranks better than 99.25% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Emmaus Life Sciences's share price is $0.01.
Emmaus Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.19. Hence, Emmaus Life Sciences's PS Ratio for today is 0.05.
Good Sign:
Emmaus Life Sciences Inc stock PS Ratio (=0.05) is close to 1-year low of 0.05.
The historical rank and industry rank for Emmaus Life Sciences's PS Ratio or its related term are showing as below:
EMMA'
s PS Ratio Range Over the Past 10 Years
Min: 0.01 Med: 2.31 Max: 130.87
Current: 0.05
During the past 13 years, Emmaus Life Sciences's highest PS Ratio was 130.87. The lowest was 0.01. And the median was 2.31.
EMMA's PS Ratio is ranked better than 99.25% of 936
companies
in the Biotechnology industry
Industry Median: 9.155
vs EMMA: 0.05
Emmaus Life Sciences Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Emmaus Life Sciences was -29.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -19.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -14.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -12.20% per year.
During the past 13 years, Emmaus Life Sciences's highest 3-Year average Revenue per Share Growth Rate was 75.10% per year. The lowest was -85.20% per year. And the median was -20.60% per year.
Back to Basics: PS Ratio
Emmaus Life Sciences (OTCPK:EMMA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Emmaus Life Sciences PS Ratio Related Terms
Emmaus Life Sciences PS Ratio Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Emmaus Life Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Emmaus Life Sciences's Share Price of today is $0.01. Emmaus Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.19.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Emmaus Life Sciences (EMMA) has a PS Ratio of 0.05 as of Jun. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Emmaus Life Sciences and its competitors. This is 98% below median its historical median of 2.31. Over the past decade, Emmaus Life Sciences' PS Ratio has ranged from 0.01 to 130.87. According to the industry distribution chart, Emmaus Life Sciences ranks #7 out of 936 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Emmaus Life Sciences' PS Ratio too high?
Emmaus Life Sciences' current PS Ratio of 0.05 is 98% below median its 10-year median of 2.31. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 130.87. The Biotechnology industry median PS Ratio is 9.16. Emmaus Life Sciences' value of 0.05 is 99.5% below this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #7 out of 936 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Emmaus Life Sciences' PS Ratio compare to PTIX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #7 out of 936 companies for PS Ratio. This places Emmaus Life Sciences in the top 1% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.16. Emmaus Life Sciences' value of 0.05 is 99.5% below this benchmark. Historically, Emmaus Life Sciences' own PS Ratio has ranged from 0.01 to 130.87 over the past decade. While the company's 10-year median is 2.31 vs. the industry median of 9.16, Emmaus Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.16, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current PS Ratio of 0.05 is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median PS Ratio is 9.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current PS Ratio is 0.05, which is 98% below median its own 10-year median of 2.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current PS Ratio is 0.05, which is 98% below median its 10-year median of 2.31 and 99.5% below the Biotechnology industry median of 9.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current PS Ratio is 0.05 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 